Long-Lasting Control of LDL Cholesterol Induces a 40% Reduction in the Incidence of Cardiovascular Events: New Insights from a 7-Year Study.

J Pharmacol Exp Ther

Department of Neuroscience, Reproductive Sciences, and Dentistry (V.T.), Department of Advanced Biomedical Sciences (R.I., P.G., M.V.M., I.F., G.S., B.T.), and Department of Public Health (D.P.), "Federico II" University, Naples, Italy; International Translational Research and Medical Education Cons

Published: February 2024


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Recent studies have yielded controversial results on the long-term effects of statins on the risk of cardiovascular (CV) events. To fill this knowledge gap, we assessed the relationship between low-density lipoprotein cholesterol (LDL-C) levels and CV events in hypertensive patients without previous CV events and naïve to antidyslipidemic treatment within the "Campania Salute Network" in Southern Italy. We studied 725 hypertensive patients with a mean follow-up of 85.4 ± 25.7 months. We stratified our cohort into three groups based on LDL cholesterol (LDL-C) levels in mg/dl: group 1) patients showing during the follow-up a mean LDL-C value ≤100 mg/dl in absence of statin therapy; group 2) statin-treated patients with LDL ≤100 mg/dl; and group 3) patients with LDL-C >100 mg/dl. No significant difference among the groups was observed in terms of demographic and clinical characteristics and medications. The incidence of first CV events was 5.7% in group 1, 6.0% in group 2, and 11.9% in group 3 ( < 0.05 vs. group 1 and group 2). A stable long-term satisfactory control of LDL-C plasma concentration (≤100 mg/dl) reduced the incidence of major CV events from one event every 58.6 patients per year to one event every 115.9 patients per year. These findings were confirmed in a Cox regression analysis, adjusting for potential confounding factors. Collectively, our data demonstrate that a 7-year stable control of LDL-C reduces the incidence of CV events by 40%. SIGNIFICANCE STATEMENT: There are several discrepancies between Mendelian studies and other investigations concerning the actual effects of reduction of plasma concentration of low-density lipoprotein (LDL) cholesterol on the incidence of major cardiovascular events. Taken together, our data in nondiabetic subjects show that a 7-year stable control of LDL cholesterol induces a ∼40% reduction of the incidence of cardiovascular events.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10877706PMC
http://dx.doi.org/10.1124/jpet.123.001878DOI Listing

Publication Analysis

Top Keywords

ldl cholesterol
16
cardiovascular events
16
≤100 mg/dl
12
events
9
control ldl
8
cholesterol induces
8
reduction incidence
8
incidence cardiovascular
8
low-density lipoprotein
8
cholesterol ldl-c
8

Similar Publications

Risk factors for coronary in-stent restenosis in Moroccan patients: a retrospective case-control study.

Cell Mol Biol (Noisy-le-grand)

September 2025

Medical School, Laboratory of Genetics and Molecular Pathology, University Hassan II, Casablanca, Morocco.

In-stent restenosis remains a significant challenge in interventional cardiology despite technological advancements. This retrospective case-control study conducted at the University Hospital Center Ibn Rochd in Casablanca (2020-2023) examined risk factors associated with coronary in-stent restenosis in 68 patients equally distributed between restenosis and no-restenosis groups. Diabetes emerged as a powerful predictor of restenosis (RR=4.

View Article and Find Full Text PDF

SIRT1 modulation and lipid profile alterations in the cellular regulation of blood lipids in renal disorders among extremely obese individuals.

Cell Mol Biol (Noisy-le-grand)

September 2025

University Sousse, Faculty of Medicine "Ibn El-Jazzar", Department of Medical Genetics, Sousse, Tunisia.

The global epidemic of overweight and obesity is closely linked to the development of chronic kidney disease (CKD), with extremely obese individuals facing a particularly high risk. This study aimed to assess the relationship between lipid profile levels, SIRT1 expression, and RNA-34a-5P in the regulation of blood lipid levels among severely obese individuals with renal diseases. Conducted over six months in three specialized hospitals, the study included 100 participants divided into two groups: 50 obese individuals with renal diseases and 50 obese controls without renal problems.

View Article and Find Full Text PDF

Lipoprotein(a) at a "Tipping Point": case to move to universal screening.

Am J Prev Cardiol

September 2025

Division of Cardiovascular Medicine, University of California San Diego, La Jolla, CA, USA.

Elevated lipoprotein(a) [Lp(a)] is well established as a common risk factor for atherosclerotic cardiovascular disease (ASCVD). Lp(a) levels are >90 % genetically determined. However, Lp(a) remains very underrecognized as a cardiovascular risk factor with low rates of testing.

View Article and Find Full Text PDF

Introduction Systemic inflammation alters lipid metabolism by suppressing hepatic lipoprotein synthesis, increasing catabolism, and impairing reverse cholesterol transport. These changes result in reduced levels of low-density lipoprotein (LDL), high-density lipoprotein (HDL), and total cholesterol (TC), despite elevated cardiovascular risk, which is a phenomenon termed the "inflammatory lipid paradox." While well-characterized in chronic inflammatory diseases, such as rheumatoid arthritis, its prevalence and clinical impact in hospitalized adults with systemic inflammation remain underexplored.

View Article and Find Full Text PDF

Introduction: We conducted a network meta-analysis (NMA) to compare the efficacy (primarily assessed by low-density lipoprotein cholesterol (LDL-C) reduction and cardiovascular event (CVE) incidence) and safety (total adverse events (AEs), neurocognitive events (NCEs), injection site reactions, infections, and all-cause mortality (ACM)) of different Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors placebo in the general population and solid organ transplant (SOT) recipients.

Materials And Methods: A total of 16 randomized controlled trials (RCTs) involving 79,615 patients were included. Cochrane risk of bias assessment tool evaluated the literature quality.

View Article and Find Full Text PDF